Tenatumomab I 131

Drug Profile

Tenatumomab I 131

Alternative Names: 131I-Tenatumomab; 131Iodine-Tenatumomab; I131 anti-Tenascin monoclonal antibody; Tenatumomab/ST2146

Latest Information Update: 16 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sigma-tau SpA
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Immunomodulators; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 04 Nov 2016 sigma-tau SpA suspends enrolment in a phase I trial in Cancer (In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in France and Italy (NCT02602067)
  • 01 Nov 2015 Phase-I clinical trials in Cancer (Second-line therapy or greater, In adults, In the elderly, Late-stage disease) in France and Italy (IV) (NCT02602067)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top